The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
复制标题
DOI：
10.1007/s10147-021-01996-8
复制
发表时间：
2021-11
影响因子：
3.3
通讯作者：
Aoki D
中科院分区：
文献类型：
--
作者：
Sekine M;Enomoto T;Watanabe Y;Katabuchi H;Yaegashi N;Aoki D
尽管广泛使用，但迄今为止（2021年6月），贝伐珠单抗10 mg/kg每2周一次（Q2 W）联合化疗方案尚未在日本获批用于铂类耐药复发性卵巢癌患者。在这项回顾性分析中，我们评估了贝伐单抗治疗铂类耐药复发性卵巢癌的使用模式。我们通过调查获得了2013年11月至2018年12月期间155家日本医疗机构的临床数据。项目包括根据剂量使用贝伐单抗治疗铂类耐药复发性卵巢癌的病例数。对于包括贝伐珠单抗10 mg/kg Q2 W的治疗方案，要求提供与伴随用药以及治疗方案的疗效和安全性相关的额外信息。在1633例复发性卵巢癌患者中报告的1739种含贝伐珠单抗的治疗方案中，264例使用10 mg/kg Q2 W。该方案的总体缓解率（ORR）为26.1%。缓解率因方案而异，当贝伐珠单抗10 mg/kg Q2 W与紫杉醇（ORR，53.0%）联合给药时，与脂质体阿霉素（15.0%; P < 0.0001）和伊立替康（7.7%; P < 0.028）相比，缓解率尤其有利。与贝伐珠单抗10 mg/kg Q2 W相关的最常见≥ 3级不良事件为中性粒细胞减少（11.7%）和高血压（11.7%）。贝伐珠单抗联合紫杉醇与贝伐珠单抗联合多柔比星脂质体组最常见的贝伐珠单抗相关≥ 3级不良事件为高血压（9.0% vs 13.9%）和蛋白尿（3.0% vs 8.4%）。贝伐珠单抗10 mg/kg Q2 W似乎对复发性卵巢癌患者有效，毒性特征可控。该方案的批准在临床上适用于日本卵巢癌患者。
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients with platinum-resistant recurrent ovarian cancer. In this retrospective analysis, we evaluated the usage patterns of bevacizumab administered for platinum-resistant recurrent ovarian cancer. We obtained clinical data from 155 Japanese medical facilities between November 2013 and December 2018 via a survey. Items included the number of cases of platinum-resistant recurrent ovarian cancer treated with bevacizumab according to dosage. For regimens including bevacizumab 10 mg/kg Q2W, additional information was requested relating to concomitantly administered agents, and the efficacy and safety of the regimen. Of 1739 bevacizumab-containing regimens reported in 1633 patients with recurrent ovarian cancer, 264 used 10 mg/kg Q2W. The overall response rate (ORR) with this regimen was 26.1%. Response rates varied according to regimen and were particularly favorable when bevacizumab 10 mg/kg Q2W was administered with paclitaxel (ORR, 53.0%) versus liposomal doxorubicin (15.0%; P < 0.0001) and irinotecan (7.7%; P < 0.028). The most frequent Grade ≥ 3 adverse events associated with bevacizumab 10 mg/kg Q2W were neutropenia (11.7%) and hypertension (11.7%). The most frequent bevacizumab-associated Grade ≥ 3 adverse events with bevacizumab plus paclitaxel versus bevacizumab plus liposomal doxorubicin were hypertension (9.0% versus 13.9%) and proteinuria (3.0% versus 8.4%). Bevacizumab 10 mg/kg Q2W appears efficacious for patients with recurrent ovarian cancer, with a manageable toxicity profile. Approval of this regimen is clinically desirable for Japanese patients with ovarian cancer.
登录
查看更多内容
影响因子：
51.1
作者：
Pfisterer, Jacobus;Shannon, Catherine M.;Kurtz, Jean-Emmanuel
通讯作者：
Kurtz, Jean-Emmanuel
影响因子：
4
作者：
Aravantinos G;Pectasides D
通讯作者：
Pectasides D
DOI：
10.3322/caac.20113
发表时间：
2011-05
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Jelovac D;Armstrong DK
通讯作者：
Armstrong DK
影响因子：
6.2
作者：
McGonigle, Kathryn F.;Muntz, Howard G.;Malpass, Thomas W.
通讯作者：
Malpass, Thomas W.
影响因子：
158.5
作者：
Burger, Robert A.;Brady, Mark F.;Liang, Sharon X.
通讯作者：
Liang, Sharon X.